Coverage / ZYME / Trade Card

ZYME

Zymeworks Inc

OPPORTUNISTIC BUY 2026-08-08 Data 35 days old USD 23.54 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
54

Position levels

Currenttoday
USD 23.54
Buy <=wait / entry
USD 18.33
Trim >=take some off
USD 27.00
Thesis breakA clinical or regulatory setback on zanidatamab, a material adverse change in pa...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case20%100 / 10020.0
Base case50%62 / 10031.0
Bear case30%10 / 1003.0
Weighted conviction54 / 100 - OPPORTUNISTIC BUY

Top risks

  • Q2 2026 EPS miss of $0.05 to $0.22 versus consensus estimates
  • Revenue of $4.59 million beat estimates but declined 90.6% YoY
  • Existing strategic partnership with Jazz Pharmaceuticals for zanidatamab development
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.